Elanco Animal Health (ELAN) Consolidated Net Income (2017 - 2026)
Elanco Animal Health (ELAN) reported Consolidated Net Income of $57.0 million for Q1 2026, down 14.93% on a YoY basis from $67.0 million in Q1 2025, and up 120.65% sequentially from -$276.0 million in Q4 2025.
Elanco Animal Health (ELAN) Consolidated Net Income (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Consolidated Net Income data on file, last reported at $57.0 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 14.93% year-over-year to $57.0 million; the trailing twelve-month figure through Mar 2026 stood at -$242.0 million (down 164.88% YoY), and the FY2025 full-year result was -$232.0 million, down 168.64% from the prior year.
- Consolidated Net Income advanced to $57.0 million in Q1 2026, from -$276.0 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $364.0 million in Q3 2024 to a low of -$1.1 billion in Q3 2023.
- A 5-year average of -$67.4 million and a median of -$10.0 million in 2022 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income surged 179.69% in 2022 and tumbled 3350.0% in 2025, its largest moves.
- Tracing ELAN's Consolidated Net Income over 5 years: stood at -$54.0 million in 2022, then tumbled by 161.11% to -$141.0 million in 2023, then soared by 94.33% to -$8.0 million in 2024, then plunged by 3350.0% to -$276.0 million in 2025, then jumped by 120.65% to $57.0 million in 2026.
- Business Quant data shows ELAN's Consolidated Net Income at $57.0 million in Q1 2026, -$276.0 million in Q4 2025, and -$34.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.00 Mn |
| Dec 31, 2025 | -276.00 Mn |
| Sep 30, 2025 | -34.00 Mn |
| Jun 30, 2025 | 11.00 Mn |
| Mar 31, 2025 | 67.00 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Sep 30, 2024 | 364.00 Mn |
| Jun 30, 2024 | -50.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | -141.00 Mn |
| Sep 30, 2023 | -1.10 Bn |
| Jun 30, 2023 | -97.00 Mn |
| Mar 31, 2023 | 103.00 Mn |
| Dec 31, 2022 | -54.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -10.00 Mn |
| Mar 31, 2022 | 51.00 Mn |
| Dec 31, 2021 | -105.00 Mn |
| Sep 30, 2021 | -108.00 Mn |
| Jun 30, 2021 | -206.00 Mn |